United States· US:0591-2520_9ea218a7-b12c-4aec-9c0b-3104b03649ce
Chlorzoxazone
A chlorzoxazone product containing chlorzoxazone, registered in United States by Actavis Pharma, Inc.. The same ATC class is registered in 3 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Chlorzoxazone is registered in 3 of 19 countries.
Countries holding a registration under ATC M03BB03 (chlorzoxazone), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 2 of them publish a price we can compare per daily dose
Chlorzoxazone · ATC M03BB03
3 / 19 countries
- Denmark
- Norwayprice
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- CHLORZOXAZONE
- Manufacturer
- Actavis Pharma, Inc.
- Country
- United States (US)
- ATC code
- M03BB03
- ATC class
- Chlorzoxazone
- Defined daily dose
- 1.5 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 4
- ndc110591252001100 TABLET in 1 BOTTLE, PLASTIC (0591-2520-01)
- ndc110591252005500 TABLET in 1 BOTTLE, PLASTIC (0591-2520-05)
- ndc110591-2520-01
- ndc110591-2520-05
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
92 interactions on record for chlorzoxazone.
Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Chlorzoxazone · interactions on record
92 records
- 8 severe
- 64 moderate
- 20 info
Most severe, free to view
- LeflunomidL04AA13severe
- TeriflunomidL04AA31severe
- LeflunomideL04AK01severe
- TeriflunomideL04AK02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Chlorzoxazone in 2 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Authorised across Europe · EMA
The same active substance is authorised in 5 EEA countries. Names it is sold under:
- Bulgaria · Миоксазон
- Denmark · Klorzoxazon Dak, Klorzoxazon Evolan
- Hungary · Myoflexin
- Romania · Clorzoxazonă Arena, Clorzoxazonă Richter
- Sweden · Klorzoxazon Evolan, Klorzoxazon Orifarm
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c6a4c3c3-707b-4ae7-9375-6b7ae0ef515a GET /v1/drugs/c6a4c3c3-707b-4ae7-9375-6b7ae0ef515a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "500",
"substance": "CHLORZOXAZONE",
"productndc": "0591-2520",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "ANDA089859",
"marketing_category": "ANDA"
}See everything about chlorzoxazone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.